- Report
- April 2025
- 50 Pages
Global
From €2412EUR$2,650USD£2,068GBP
- Report
- February 2025
- 200 Pages
Global
From €4086EUR$4,490USD£3,503GBP
- Report
- May 2023
- 180 Pages
Global
From €5415EUR$5,950USD£4,642GBP
- Report
- March 2022
- 300 Pages
Global
From €4551EUR$5,000USD£3,901GBP
- Report
- April 2025
- 50 Pages
Global
From €2412EUR$2,650USD£2,068GBP
- Report
- April 2025
- 50 Pages
Global
From €2412EUR$2,650USD£2,068GBP
Orphenadrine is a centrally acting muscle relaxant used to treat muscle spasms and pain. It is classified as a centrally acting skeletal muscle relaxant, and is commonly used to treat conditions such as muscle spasms, muscle pain, and tension headaches. It works by blocking the action of certain nerve impulses in the brain, which helps to reduce muscle spasms and pain. Orphenadrine is available in both oral and injectable forms, and is often used in combination with other medications to treat muscle spasms and pain.
Orphenadrine is a popular choice for treating muscle spasms and pain, as it is generally well tolerated and has few side effects. It is also relatively inexpensive, making it an attractive option for those looking for an effective treatment for muscle spasms and pain.
The Orphenadrine market is a part of the larger Central Nervous System Drugs market, which includes a variety of medications used to treat conditions such as depression, anxiety, and insomnia. The Central Nervous System Drugs market is a highly competitive market, with many companies competing for market share.
Some of the companies in the Orphenadrine market include Pfizer, Novartis, Merck, and GlaxoSmithKline. Show Less Read more